Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 323

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 323
---
 on our consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.

80

The following table provides a summary of activities with respect to accrued product returns and rebates for the years ended December 31, 2024 and 2023 (dollars in thousands):Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2023$57,290 $96,984 $10,719 $164,993 ProvisionProvision for current year sales17,677 389,842 69,589 477,108 Adjustments relating to prior year sales(11,943)(2,049)(42)(14,034)Total provision5,734 387,793 69,547 463,074 Less: Actual payments/credits(9,649)(369,447)(67,919)(447,015)Balance at December 31, 2024$53,375 $115,330 $12,347 $181,052 Balance at December 31, 2022$45,008 $106,657 $12,995 $164,660 ProvisionProvision for current year sales22,928 406,329 65,896 495,153 Adjustments relating to prior year sales(213)1,672 31 1,490 Total provision22,715 408,001 65,927 496,643 Less: Actual payments/credits(10,433)(417,674)(68,203)(496,310)Balance at December 31, 2023$57,290 $96,984 $10,719 $164,993 

Accrued Product Returns and Rebates 

The accrued product returns balance decreased from $57.3 million as of December 31, 2023 to $53.4 million as of December 31, 2024. This decrease was primarily due to $11.9 million of adjustments in the estimated provision for product returns related to prior year sales offset by higher net product sales and timing of related return activity. The majority of the adjustment is attributable to Qelbree, reflecting favorable actual returns experienced in 2024. As